1
|
Datoguia TS, Velloso EDRP, Helman R, Musacchio JG, Salvino MA, Soares RA, Higashi M, Fadel AV, E Silva RSA, Hamerschlak N, Santos FPDS, Campregher PV. Overall survival of Brazilian acute myeloid leukemia patients according to the European LeukemiaNet prognostic scoring system: a cross-sectional study. Med Oncol 2018; 35:141. [PMID: 30187210 DOI: 10.1007/s12032-018-1179-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2018] [Accepted: 06/19/2018] [Indexed: 10/28/2022]
Abstract
Prognostic stratification in acute myeloid leukemia (AML) relies, mostly, on cytogenetics and molecular features of leukemic blasts. The LeukemiaNet prognostic scoring system has been proposed as a standardized way of evaluating prognosis in AML. We have analysed outcomes in 65 AML cases (median age of 54 years, range 18-82) treated at five hematology centers in Brazil stritified according to the European Leukemia Net (ELN) recommendations for cytogenetic and molecular analysis. We classified patients as favorable (N = 13), intermediate-1 (N = 25), intermediate-2 (N = 15), or adverse risk (N = 9). Bone marrow transplantation (BMT) was performed in 13 patients (21%). Median follow-up was 12 months. The median overall survival (OS) for all patients was 12.4 months. Median OS was 19.8, 12.4, 10.1, and 10.4 months (p = 0.24) for patients in the favorable, intermediate-1, intermediate-2, and adverse groups, respectively. Among patients receiving BMT, median OS was 26.8 months. The ELN is a valuable tool for prognostic stratification of AML patients treated in Brazil. Nevertheless, its usefulness is limited when compared to data from developed countries.
Collapse
Affiliation(s)
- Tarcila Santos Datoguia
- Centro de Pesquisa Clínica, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
| | | | - Ricardo Helman
- Centro de Pesquisa Clínica, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
| | | | - Marco Aurélio Salvino
- Complexo Hospitalar Universitário Professor Edgard Santos (HUPES), Universidade Federal da Bahia (UFBA), Salvador, Brazil
| | | | | | | | | | - Nelson Hamerschlak
- Centro de Pesquisa Clínica, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
| | | | - Paulo Vidal Campregher
- Centro de Pesquisa Clínica, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil. .,Centro de Pesquisa Clínica, Instituto Israelita de Ensino e Pesquisa Albert Einstein, Av. Albert Einstein, 627/520, São Paulo, CEP 05256-900, Brazil.
| |
Collapse
|